The tumor-immune microenvironment also matters: stromal tumor-infiltrating lymphocytes (TILs), standardized by the International TILs Working Group, consistently predict higher pCR and favorable outcomes—most notably in TNBC and increasingly in HER2-positive disease [11,12,13]. The gene discussed is ERBB2; the disease is neoplasm.